News and publications
Promethera Biosciences and EMD Millipore join forces to deliver a pre-clinical liver pharmaco-toxicological testing assay
Mont-Saint-Guibert (Belgium) and Billerica, MA (USA) – March 10, 2014 – Promethera® Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism. Early availability of reliable human liver-based assays is critical to the pharmaceutical industry when deciding to bring a lead compound in clinical phase development... [PDF]
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01